Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies - CNRS - Centre national de la recherche scientifique
Article Dans Une Revue Human Gene Therapy Année : 2000

Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies

M. Marin
  • Fonction : Auteur
A. Oates
  • Fonction : Auteur
R. Saller
  • Fonction : Auteur
B. Salmons
  • Fonction : Auteur

Résumé

Continuous and sustained in vivo production of monoclonal antibodies by engineered cells might render long-term antibody-based treatments cost-effective, avoid side effects associated with infusion of massive doses of antibody, and circumvent possible antiidiotypic responses against the therapeutic agent. The FrCasE retrovirus induces a lethal neurodegeneration on infection of newborn mice. We report here that implantation of cellulose sulfate capsules containing cells secreting an ectopic monoclonal antibody neutralizing FrCasE can prevent animals from developing the disease. All treated mice showed reduced or undetectable viremia in addition to a lack of the histopathological lesions characteristic of FrCasE infection. This work paves the way for a novel gene/cell antibody-based immunotherapy of a variety of severe viral and nonviral diseases.
Fichier non déposé

Dates et versions

hal-02196828 , version 1 (29-07-2019)

Identifiants

Citer

M. Pelegrin, M. Marin, A. Oates, D. Noel, R. Saller, et al.. Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies. Human Gene Therapy, 2000, 11 (10), pp.1407--15. ⟨10.1089/10430340050057486⟩. ⟨hal-02196828⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

More